CureVac, whose vaccine comes with easier storage requirements than other mRNA shots, laid out a possible path to salvage its vaccine, emphasizing its utility in people 18 to 60 years old. In that age group, overall efficacy was 53 percent, with much stronger…
$60,000 level in focus as crypto slides
February 28, 2026
